The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches see the Parkinson's disease market grow at a compound annual growth rate (CAGR) of 2.6% over the next 10 years (20082018).
Reasons to Purchase
Quantify the performance of each of the marketed Parkinson's disease drugs in the seven major markets over the period 2008 to 2018.
Assess the changing key opportunities and threats affecting current market players and prospective new entrants.
Identify the leading brands in this market over the next 10 years and understand the key factors driving their success.